New research led by the University of Portsmouth has revealed how Duchenne muscular dystrophy (DMD), best known for causing ...

Participants in the FORWARD-53 trial had clinically significant improvements in time-to-rise, among other metrics.

An 8-year-old northern Minnesota boy is one of the first in the country to receive a specific type of gene therapy treatment.

WVE-N531 demonstrated statistically significant improvements in muscle biopsy measures and functional measures in patients ...

Dec. 16, 2024 — A novel drug holds promise for treating Duchenne muscular dystrophy (DMD), a rare genetic disorder that causes severe muscle degeneration. Researchers have discovered that an ...

Wave Life Sciences’ experimental treatment for Duchenne muscular dystrophy hit the mark in a mid-stage study, setting the ...

Duchenne muscular dystrophy (DMD) is a disorder that causes progressive muscle weakness and a loss of function. The symptoms appear early in life, and most affected individuals require the use of ...

Amid readouts from the Muscular Dystrophy Association’s annual meeting, the Clinical Trials Arena evaluates five DMD trials ...

WVE-N531, an oligonucleotide, elicited significant functional benefit and reversal of muscle damage in the Phase II ...

Muscular Dystrophy Association (MDA) has teamed up with Burn Boot Camp, a leading boutique fitness franchise, for the 9th annual national 'Be Their Muscle' philanthropic event. Throughout April, over ...

The Cambridge-based biotech's experimental treatment for Duchenne muscular dystrophy hit the mark in a mid-stage study, ...